Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : CEAPRO INC.----CZO -- Ignore unavailable to you. Want to Upgrade?

To: PJ who wrote (16)	9/14/1998 2:25:00 PM
From: Mark J. Redmond	Read Replies (1) \| Respond to of 53

Standard & Poors No.12G Reg.823486 For Immediate Release NEWS RELEASE CEAPRO INC. - NEW DIRECTORS Edmonton - August 14, 1998-- Ceapro Inc. ("Ceapro") (ASE: CZO) announced today the appointment of three new Directors, subject to regulatory approval. Joining the Ceapro Inc. Board of Directors are Mr. John Zupancic, Mr. Ken Ruptash, and Mr. Peter Ulrich. Mr. Zupancic is a significant Ceapro shareholder and has been a shareholder since the early stages of Ceapro. Mr. Zupancic is an entrepreneur and management consultant involved in technology commercialization. Prior to this, he was President and CEO of the Alberta Microelectronic Centre. Mr. Ken Ruptash, a shareholder in Ceapro Inc., is Vice President and General Manager of Midwest Television Ltd. and Sask-Alta Broadcasters Limited, operators of CITL-TV, CKSA-TV, and CKSA Radio. Mr. Ruptash is also a Director of Craig Broadcasting, Alberta. Mr. Ulrich is President and CEO of NeuroVir Inc., a biopharmaceutical company based in Vancouver, British Columbia, which is developing products to treat cancer, nervous system diseases, and other disorders. Prior to this, Mr. Ulrich was Executive Vice President of La Jolla Pharmaceutical Co. in San Diego, California. Messrs. Zupancic, Ruptash, and Ulrich bring to Ceapro extensive business, technology, and pharmaceutical experience. "We are delighted to have these three people join the Ceapro Board," stated Bob Binnendyk, President and CEO. Ceapro has developed a novel Diabetes Screening Product for the purpose of identifying people who have Impaired Glucose Tolerance or Type II Diabetes. Ceapro is in the advanced stages of discussions with a major international pharmaceutical company relative to this product. -30- For more information contact Robert A. Binnendyk, President & CEO Ceapro Inc. Telephone (403) 421-4555 - The ASE has neither approved nor disapproved of the information contained herein -

To: PJ who wrote (16)	9/14/1998 2:27:00 PM
From: Mark J. Redmond	Read Replies (1) \| Respond to of 53

Standard & Poors No.12G Reg.823486 For Immediate Release NEWS RELEASE CEAPRO INC. - PRIVATE PLACEMENT Edmonton - August 13, 1998-- Ceapro Inc. ("Ceapro") (ASE: CZO) announced today its intention to complete a private placement of up to 4.3 million Units at a price of $0.80 per Unit. The offering is subject to regulatory approval and is expected to generate gross proceeds of a minimum of $1,500,000 and a maximum of $3,000,000. Each consists of one common share and one-half share purchase warrant. Each full purchase warrant will entitle the holder to acquire one common share at a price of $1.00 and may be exercised within two years of closing. As at August 12, 1998 the Company has received subscriptions in excess of the minimum required to close this placement i.e. $1,500,000. The offering is being sold primarily through the directors and officers of the Company, in which case no commissions will be paid. Commissions to a maximum of 5% may be payable to third parties who are at arm's length to the Company in respect of any units sold by that party. The proceeds from the offering will be used to pay all remaining debt in the Company, including bank debt and unsecured creditors. The balance will be retained and used as working capital for the development and market development of new products. -30- For more information contact Ceapro Inc.: Telephone (403) 421-4555 Robert A. Binnendyk, President & CEO - The ASE has neither approved nor disapproved of the information contained herein